Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pain block could cut opioid use after gynecologic surgery

NCT ID NCT06575699

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times

Summary

This study tested whether a rectus sheath block (a type of nerve block) using liposomal bupivacaine can reduce the need for opioid painkillers after gynecologic cancer surgery. Thirty patients received the block and were compared to 60 similar patients who had epidural pain relief. The main goal was to measure opioid use in the first 72 hours after surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNECOLOGIC SURGICAL PROCEDURES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

liposomal bupivacaine and bupivacaine hydrochloride

What this could lead to

If successful, this approach could offer a simpler, effective pain control method after gynecologic cancer surgery, potentially reducing opioid use and side effects.

What could go wrong

This is a small pilot study with only 30 participants receiving the block, compared to historical controls. Results may not apply to all patients, and the block may not be as effective as epidural analgesia.

Conditions

The condition(s) this trial relates to.

female reproductive organ cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.